Circulating adipokines and risk of obesity related cancers: A systematic review and meta-analysis
- Authors
- Yoon, Yeong Sook; Kwon, A. Rom; Lee, Yoon Kyung; Oh, Sang Woo
- Issue Date
- Jul-2019
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Obesity; Cancer; Adipokine; Inflammation; Meta-analysis
- Citation
- OBESITY RESEARCH & CLINICAL PRACTICE, v.13, no.4, pp 329 - 339
- Pages
- 11
- Indexed
- SCIE
SCOPUS
- Journal Title
- OBESITY RESEARCH & CLINICAL PRACTICE
- Volume
- 13
- Number
- 4
- Start Page
- 329
- End Page
- 339
- URI
- https://scholarworks.dongguk.edu/handle/sw.dongguk/7935
- DOI
- 10.1016/j.orcp.2019.03.006
- ISSN
- 1871-403X
1878-0318
- Abstract
- Background: Obesity can influence on carcinogenesis through alterations in adipokines and subsequent inflammatory changes. This meta-analysis was aimed to comprehensively assess the association between circulating adipokines and risk of obesity-related cancers. Methods: Pubmed and Embase were searched up to October 2017 for observational studies investigating the relationship between adipokines and cancers. Pooled odds ratio and the corresponding 95% confidence interval was estimated through the meta-analysis using a random-effects model. Findings A total of 93 observational studies (adiponectin = 60, high molecular weight adiponectin = 9, leptin = 39, IL-6 = 16, TNF-alpha = 10, and resistin = 17) were included. Adiponectin was significantly associated with decreased risk of cancer (pooled OR 0.70, 95% CI 0.60-0.80; I-2 = 71.9%; P-heterogeneity < 0.01). Leptin was significantly associated with increased risk of cancer (1.26, 1.05-1.51; I-2 = 65.7%; P-heterogeneity < 0.01). For each 5 mu g/ml increase in adiponectin and 5 ng/ml increase in leptin, the pooled OR was 0.88 (0.83-0.93; I-2 = 80.2%; P-heterogeneity < 0.01) and 1.05 (1.01-1.09; I-2 = 67.9%; P-heterogeneity < 0.01)), respectively. There was nonlinear dose-response association (P-nonlinearity for adiponectin = 0.01; P-nonlinearity for leptin = 0.003). IL-6 (1.09, 0.94-1.25), TNF-alpha (1.65, 0.99-2.74), and resistin (1.28, 0.78-2.11) was not associated with risk of cancer. By cancer site and type, highest category of adiponectin was associated with decreased risk of breast (OR 0.74, 0.60-0.91), colorectal (0.74, 0.60-0.91), and endometrial cancer (0.49, 0.34-0.72). Higher leptin was associated with increased risk of endometrial (1.88, 1.24-2.87) and kidney cancer (2.07, 1.51-2.83). Conclusion: Our study suggests that adiponectin and leptin may play a role in the etiology of cancer. (C) 2019 Published by Elsevier Ltd on behalf of Asia Oceania Association for the Study of Obesity.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Medicine > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.